These independent CME/CE activities are supported by an educational grant from UCB, Inc..



       Rheumatology Mastery in
   Rheumatoid
   Arthritis
  1. Course List
Chair
M. Elaine Husni, MD, MPH
  • Vice Chair
  • Department of Rheumatic & Immunologic Diseases
  • Cleveland Clinic
  • Cleveland, Ohio

  • Contributing Editor
    Jeffrey R. Curtis, MD, MS, MPH
  • William J. Koopman Endowed Professor in Rheumatology and Immunology
  • Director, UAB Arthritis Clinical Intervention Program
  • University of Alabama at Birmingham
  • Birmingham, Alabama

  • Daniel Furst, MD, MSPH
  • Daniel E Furst, MD
  • Director of Therapeutic Research
  • Rheumatology
  • University of California Los Angeles
  • Los Angeles, CA

  • Aprajita Jagpal, MBBS, MD
  • Rheumatology Fellow
  • University of Alabama at Birmingham
  • Birmingham, Alabama

  • John R. P. Tesser, MD
  • Rheumatologist
  • Arizona Arthritis & Rheumatology Associates
  • Phoenix, Arizona

  • Michael H. Weisman, MD
  • Professor of Medicine
  • Department of Rheumatology
  • Cedars-Sinai Medical Center
  • Los Angeles, California
  • Disclosure Information
    M. Elaine Husni, MD, MPH   M. Elaine Husni, MD, MPH, has received consulting fees from AbbVie, Inc., Amgen, Bristol-Myers Squibb, Janssen Pharmaceuticals, Inc., Pfizer Inc, Regeneron, and UCB, Inc.

    Jeffrey R. Curtis, MD, MS, MPH   has disclosed: Salary/honoraria: Roche/Genentech, UCB, Centocor, Corrona, Amgen, Pfizer, BMS, Crescendo, Abbott

    Daniel Furst, MD, MSPH   has received contracted research support from AbbVie Inc, Amgen Inc, Actelion Pharmaceuticals US, Inc, Bristol-Myers Squibb, Corbus Pharmaceuticals, NIH, Novartis Pharmaceuticals Corporation, Pfizer Inc, and Roche/Genentech; and has received consulting fees from AbbVie Inc, Amgen Inc, Actelion Pharmaceuticals US, Inc, Bristol-Myers Squibb, Cytori Therapeutics, Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc, and Roche/Genentech.

    Aprajita Jagpal, MBBS, MD   has disclosed no relevant relationships.

    John R. P. Tesser, MD   has received grant/research support from AbbVie, Inc, Ablynx, Amgen Inc, Astra Zeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Genentech, GlaxoSmithKline, Janssen, Lilly, Novartis Pharmaceuticals, Pfizer Inc, Sandoz, and UCB Inc.; is on the speaker’s bureau for AbbVie, Inc, Amgen Inc, Bristol-Myers Squibb, Crescendo Biosciences, Genentech, Janssen, Lilly, Medac, and Pfizer Inc.; and is a consultant for/on the advisory board of Amgen Inc, Bristol-Myers Squibb, Crescendo Biosciences/Mallinkrodt, Genentech, Janssen, Lilly, Medac, Pfizer Inc., UCB Inc., and Sanofi-Genzyme/Regeneron.

    Michael H. Weisman, MD   has received consulting fees from Ampel Biosolutions LLC, Ionis Pharmaceuticals, and UCB, Inc.; and has received expert witness fees from Tharpe & Howell and Paul Hastings LLP.